Is Dermata Therapeutics, Inc. (DRMA) a Buy, Sell, or Hold?
NASDAQ : DRMA
Dermata Therapeutics, Inc.
$1.28 USD
-$0.02 (-1.54%)
- Volume
- 49.1K
- Average Volume
- 70.88K
- Market Capitalization
- $872.39K
- P/E Ratio
- -0.24
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $7.50
- Year Low
- $1.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.09
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Gerald T. Proehl |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DRMA |
| CUSIP | 249845504 |
| CIK | 0001853816 |
| Web | https://www.dermatarx.com |
| Phone | 858 800 2543 |
| Currency | USD |
| Employees | 9 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.09 |
| Quick Ratio | 7.00 |
| Cash Ratio | 6.60 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -2.15 |
| Price / Cash Flow | -0.11 |
| Price / Book | 0.78 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -78.67% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$8.16 |
| Trailing P/E Ratio | -0.24 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$7.56M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -127.91% |
| Return on Assets | -95.14% |
Financials Score
| AltmanZ Score | -15.75 |
| Piotroski Score | 1.00 |
| Working Capital | 6.41M |
| Total Assets | 7.47M |
| Ebit | -7.22M |
| Market Cap | 865.58K |
| Total Liabilities | 1.05M |
Poll Results
About Dermata Therapeutics, Inc. (NASDAQ:DRMA) Stock
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, Cali ... fornia.
2026-05-13 16:05:00
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 - - Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility - SAN DIEGO, CA / ACCESS Newswire / May 13, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2026. "Since announcing our strategic pivot in September 2025, we have made meaningful progress toward becoming a direct-to-consumer commercial skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO.
Frequently Asked Questions
-
What is the current Dermata Therapeutics, Inc. (DRMA) stock price?
-
Dermata Therapeutics, Inc.(NASDAQ:DRMA) stock price is $1.28 in the last trading session. During the trading session, DRMA stock reached the peak price of $7.5 while $1.1 was the lowest point it dropped to. The percentage change in DRMA stock occurred in the recent session was --1.54% while the dollar amount for the price change in DRMA stock was -$0.02.
-
DRMA's industry and sector of operation?
-
The NASDAQ listed DRMA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DRMA?
-
Maria Bedoya Toro Munera | Senior Vice President of Regulatory Affairs & Quality Assurance
David F. Hale | Co-Founder & Lead Independent Director
Kyra Peckaitis | Vice President of Marketing
Christopher J. Nardo | Senior Vice President & Chief Development Officer
Kyri K. Van Hoose | Senior Vice President & Chief Financial Officer -
How many employees does DRMA have?
-
Number of DRMA employees currently stands at 9. DRMA operates from 3525 Del Mar Heights Road, San Diego, CA 92130, US.
-
Link for DRMA official website?
-
Official Website of DRMA is: https://www.dermatarx.com
-
How do I contact DRMA?
-
DRMA could be contacted at phone #858 800 2543 and can also be accessed through its website. DRMA operates from 3525 Del Mar Heights Road, San Diego, CA 92130, US.
-
How many shares of DRMA are traded daily?
-
The average number of DRMA shares traded daily for last 3 months was 70.88K.
-
What is the market cap of DRMA currently?
-
The market value of DRMA currently stands at $872.39K with its latest stock price at $1.28